Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SRI-43887
- Development stage
- Preclinical
- Lead developer
- Southern Research
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
SRI-43887 (also referred to as duali) is a novel small-molecule dual inhibitor of receptor-interacting serine/threonine-protein kinase 3 (RIPK3) and bromodomain-containing protein 4 (BRD4). Developed by Southern Research and the University of Alabama at Birmingham, the compound is designed to target necroptotic and inflammatory pathways that are upregulated following exposure to arsenical chemical warfare agents, such as lewisite. In preclinical models of arsenical-induced acute kidney injury (AKI) and skin injury, SRI-43887 has demonstrated protective efficacy, including the recovery of glomerular filtration rate and reduction of inflammatory markers like interleukin-6 (IL-6).
- Other names
- duali
02
Targets
BRD4 (Bromodomain-containing protein 4)RIPK3
Beyond the preview
Go deeper on SRI-43887.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SRI-43887.